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Coronary heart disease (CHD) remains the leading cause of death in the United States. National review of Emergency Department
(ED) visits from 2007 to 2008 reveals that 9% are for chest pain. Of these patients, 13% had acute coronary syndromes (ACSs)
(Antman et al., 2004). Plaque rupture with thrombus formation is the most frequent cause of ACS, and identifying patients prior
to this event remains important for any clinician caring for these patients. There has been an increasing amount of research and
technological advancement in improving the diagnosis of patients presenting with ACS. Low-to-intermediate risk patients are
the subgroup that has a delay in deﬁnitive treatment for ACS, and a push for methods to more easily and accurately identify the
patients within this group that would beneﬁt from an early invasive strategy has arisen. Multiple imaging modalities have been
studied regarding the ability to detect ischemia or wall motion abnormalities (WMAs), and an understanding of some of the
currently available noninvasive and invasive imaging techniques is important for any clinician caring for ACS patients.
1.Introduction
CHD continues to remain the leading cause of death in
the United States (USA), and the prevalence has increased
worldwide as diets continue to “westernize”. Of the nearly
5.5 million visits annually for chest pain, <10% of patients
present with ST segment elevation [1], and of the remaining
patients only ∼13% have ACS [2]. There is signiﬁcant
morbidity and mortality associated with ACS and a sig-
niﬁcant cost in excluding it. National ﬁgures estimate ∼10
billion dollars are spent annually in excluding ACS in
the USA. As economic markets and turmoil continue to
aﬀect the healthcare landscape, there is increased scrutiny
on methods to control cost while improving diagnosis.
Physicians and scientists worldwide have thus sought ways
to improve the accuracy and speed of diagnosis by studying
methods that detect coronary artery disease (CAD) either
by identifying decreased perfusion or the consequences of
decreased perfusion. Methods aimed at detecting ischemia
or regional wall motion abnormalities (RWMAs). Patients
with ACS are increasingly being managed with invasive
strategies,butmethodstoidentifypatientsthatwouldbeneﬁt
from this strategy earlier in their presentation are vital to
improve care.Imagingtools thathavebeen evaluatedinclude
noninvasive measures like contrast echocardiography, mul-
tidetector computed tomography (MDCT), single photon
emission tomography (SPECT), nuclear perfusion imaging,
positron emission tomography (PET), cardiac magnetic
resonance imaging (CMR), and even invasive techniques
like intravascular ultrasound (IVUS) and optical coherence
tomography (OCT). The most eﬀective tool would be very
speciﬁc and sensitive, rapid, cost-eﬀective, noninvasive, and
able to be performed bedside. None of the aforementioned
tools fulﬁll all of these, but they all have signiﬁcant roles
and provide important diagnostic information that aides the
clinician in the diagnosis of ACS. A review of these imaging
modalities and their strengths and weaknesses is important
information for any clinician managing patients with ACS.
Analysis by Fox et al. of the global registry of acute
coronary events (GRACEs) revealed that between 1999 and
2006 improvements in managements of patients with ACS
were associated with a decrease in the rates of heart failure
and mortality [3]. Rates of cerebrovascular accidents and
myocardial infarction were reduced. During this time, rates
of percutaneous coronary interventions (PCIs) increased by
∼18%. The 2011 update in patients with ACS supports2 ISRN Cardiology
Table 1: ACS imaging modalities.
Cost Invasiveness Portability Timeliness Main limitations
Echocardiography + + +++ +++
Poor acoustic windows, low speciﬁcity,
operator-dependent acquisition,
subjective
Computed tomography ++ + + +++
Inability to image lesions with heavy
calcium burden, IV contrast, radiation
exposure
Cardiac MRI +++ + + + Acquisition time, unstable patients,
metallic fragments
Positron emission tomography +++ + + +
Limited spatial resolution, ionizing
radiation, requires coregistration with CT
or MRI, hindered by cardiac and
respiratory motion
Single photon emission tomography ++ + + +
longer imaging protocols for stress rest
comparison, radiation exposure, lower
spatial resolution than echocardiography
underestimate three vessel CAD due to
balanced ischemia, attenuation artifacts
IVUS/OCT +++ +++ + +
Time consuming each coronary artery
must be imaged separately, limited spatial
resolution of >100µm with IVUS, limited
depth penetration with OCT
Key: + least, ++ moderate, +++ most.
an early invasive strategy for those with refractory angina or
continued instability and in those elevated risk as a class I
recommendation. Meta-analyses of early invasive strategies
have revealed that routine invasive strategies had an 18%
relative reduction in death or myocardial infarction (MI),
and a signiﬁcant reduction in MI alone [4]. Experience and
evidence shows that patients presenting with ST segment
elevation myocardial infarction (STEMI), high-risk unstable
angina (UA), and non-ST segment elevation myocardial
infarction (NSTEMI) beneﬁt from an early invasive strategy.
Angiography remains the gold standard for these patients.
The question remains regarding low- and intermediate-risk
patients and the most eﬀective way of establishing whether
CHD is present or absent. No currently available tool is
both 100% sensitive and speciﬁc for ACS. A summary of
the imaging modalities that currently available as well as
strengths and limitations are listed in Table 1 and will be
discussed further. The electrocardiogram (EKG) is still one
of the most important methods a clinician has in making
this early distinction, but the EKG does little to establish a
diagnosis unless positive in the acute setting.
2.Echocardiography
Echocardiography can rapidly assess for RWMA, is highly
portable, and relatively inexpensive compared with other
noninvasive modalities. Echocardiography relies on detect-
ing wall motion changes, which occur when myocardial
blood ﬂow falls below resting levels. Often this occurs
when coronary obstruction exceeds 85–90% of the luminal
area [5]. Myocardial blood ﬂow aﬀects myocardial oxygen
consumption. When there is a supply-demand mismatch,
myocardial contractility is aﬀected and leads to the devel-
opment of hypokinesis [6]. Echocardiography is a class
I indication to evaluate RWMA in patients presenting
with chest pain but with low-to-intermediate risk. Earlier
discussions have revealed that echocardiography had a
high sensitivity (92-93%) in detecting AMI and cardiac
ischemia (88%) in patients presenting to the ED with
chest pain [7]. The speciﬁcity was only 53–57% in this
same group. The addition of contrast echocardiography has
been employed to improve these parameters. Myocardial
contrast echocardiography (MCE) has been used to evaluate
RWMA and to assess microvascular perfusion. A decrease
in myocardial blood ﬂow (MBF) results in a reduction
in myocardial blood volume, and with MCE a perfusion
defect can be visualized. Evaluation of MCE in a multicenter
study when compared with single photon emitted computed
tomography found that the two were similar in their ability
to identify and diagnose those with AMI [8]. Lønnebakken
et al. [9] used MCE to prioritize patients with NSTEMI
and angiographically severe CAD. Their study used a wall
motion score compromising the 17 segments left ventricular
model and myocardial perfusion followed by CAD assess-
ment invasively measured by quantitative coronary analysis
(QCA). Results from this study found that patients with
≥6 hypoperfused left ventricular segments had a 7-fold
higher risk of severe CAD. Their ﬁndings were not speciﬁc
for the area of stenosis unless it involved the proximal left
anterior descending (LAD) coronary artery. Limitations in
echocardiography are often the result of limited or poor
acoustic windows, its poor speciﬁcity, operator-dependent
acquisition, and is one of the most subjective imaging
modalities.ISRN Cardiology 3
3. Computed Tomography
MDCT has been studied extensively to determine its role in
the noninvasive assessment of ACS. MDCT has the ability
to identify plaque area and the degree of stenosis. The
sensitivity of MDCT to detect CAD has been reported to be
73–100% with a speciﬁcity of 91–97% [10–12]. MDCT has
good correlation with IVUS [13] and coronary angiography
[14]. A study by Hoﬀmann et al. [15] used MDCT to
comparelesioncharacteristicsinculpritlesionsfrompatients
with ACS, stable lesions in patients with ACS, and stable
lesions in patients with stable angina. Lesions that were
detected by MDCT correlated well to coronary angiography
thus possibly serving as a method to further risk stratify
patients with ACS. All lesions that had impaired image
quality were not included in the analysis. MDCT studies
have also sought to deﬁne the high-risk characteristics in
lesions that may make patients more susceptible to ACS.
Detection of low attenuation of <30 Hounsﬁeld units and
positive remodeling has proven very accurate in predicting
future ACS [16]. Recent work [17] has shown that MDCT
can predict thin cap ﬁbroatheromas (TCFA) and vulnerable
plaque by identifying low attenuation, a large remodeling
index, and a signet ring-like appearance. These predictors
correlated well with OCT. Motoyama et al. [16] studied
coronary artery lesions in patients with NSTEMI, STEMI, or
unstable angina presenting >24 hours after symptoms onset
whom were symptom-free and hemodynamically stable.
Culprit lesions in patients with ACS are characterized by
large plaque volume, necrotic cores and local inﬂammation.
MDCT studies with IVUS and OCT have also conﬁrmed
that high attenuation around the coronary artery plaque
was more susceptible to rupture [18]. MDCT is limited by
its inability to image lesions with heavy calcium burden,
necessitates the use of intravenous contrast, and requires
radiation exposure. The greatest asset of MDCT may be the
negative predictive value for excluding signiﬁcant CAD in
those at low-to-intermediate risk presenting with chest pain.
4.CardiacMagnetic Resonance Imaging
The role of CMR has clear roles in the congenital heart
disease, chronic CAD, myocardial and pericardial diseases,
and imaging of the great vessels. CMR has a sensitivity of
84% and a speciﬁcity of 85%, which is greater than EKG
or troponin and more speciﬁc than an abnormal troponin
[19]. There are multiple methods that CMR employs to
establish a diagnosis of ACS. CMR cine imaging can assess
global and regional left ventricular function, and its accurate
and reproducible ventricular volumes and functions make
it more accurate than other noninvasive methods [20].
First pass myocardial perfusion utilizes a contrast agent
coadministeredwithavasodilator-likeadenosinetodelineate
under perfused areas highlighting subendocardial ischemia.
The MR-IMPACT study evaluated 234 patients with CMR
andSPECT,andCMRwasbetteratdetectingcoronaryartery
stenosis than SPECT [21]. CMR has been used to evaluate
microvascular obstruction (MVO). Imaging within the ﬁrst
few minutes of contrast administration can detect MVO
by revealing decreased contrast delivery to the infarcted
area and decreased signal intensity on T1-weighted imaging.
Myocardium that is acutely or chronically infarcted that
does not have MVO will retain contrast and have bright
signal intensity on T1-weighted images. Viability can be
assessed utilizing CMR via late gadolinium enhancement.
Ten to twenty minutes after contrast administration, delayed
imaging can highlight the extent of the scar and potential for
functional recovery. CMR can also detect myocardial edema
often present in acute injury with T2-weighted images, and
coronary CMR angiography can detect proximal coronary
artery stenosis. The evaluation of CMR as an imaging
modality for the stratiﬁcation of patients presenting to the
ED with chest pain has been extensively evaluated, and it
can identify ACS more predictably than EKG, troponin, and
TIMI score [19]. Plein et al. [22] studied NSTEMI patients
2–5 days after presentation and concluded that CMR reliably
predicted coronary stenosis necessitating revascularization
conﬁrmed by angiography. CMR also can ﬁll a vital role in
diﬀerentiating ACS from other myocardial diseases such as
myocarditis and can detect complications from ACS such
as left ventricular thrombus, ventricular septal defects, and
aneurysms[23].DespiteadvancesinCMRtechniquesseveral
limitations persist. Acquisition times are lengthy, unstable
patients and patients without new generation pacemakers or
withmetallicfragmentsarenotcandidates,anditisrelatively
expensive, and is not portable. CMR with its limitations still
remains a viable option in the diagnosis and stratiﬁcation of
patients presenting with chest pain.
5. Positron Emission Tomography
PET with 18F-ﬂuorodeoxyglucose (FDG) is able to identify
functional metabolic activity by imaging glucose utilization.
FDG once injected is taken up by cells that utilize glucose
for metabolism, and the more metabolic activity of the tissue
the greater the amount of FDG, taken up. As FDG decays
gamma rays are emitted and the position of origin is imaged
by PET imaging. The majority of FDG PET for cardiac
applications is assessing viability, but interest in its use for
ACS has arisen due to its high sensitivity for molecular
targets. Imaging with PET in ACS relies on the ability to
detect acute inﬂammation. Atherosclerotic coronary plaques
are characterized by macrophage accumulation. FDG uptake
is increased in these areas as macrophages often take up
more glucose than the surrounding tissues [24, 25]. PET has
limited spatial resolution of 3–5mm making reproducible
measurementsintherightcoronaryartery(RCA)andmidto
distal vessels somewhat problematic. PET is further limited
as it uses ionizing radiation, requires coregistration with
CT or MRI for localization, and is hindered by cardiac and
respiratory motion [26, 27]. Studies employing a diet rich
in free fatty acids prior to imaging leads to a decrease in
myocardial uptake of tracer without aﬀecting other tissue
improving coronary artery imaging [28]. PET, due to its
ability to detect increased metabolic activity, may help
identify vulnerable high risk plaque that is not obstructive
to blood ﬂow due to positive remodeling, but still prone to
rupture and subsequent ACS.4 ISRN Cardiology
6. Single Photon Emission
Computed Tomography
Myocardial perfusion imaging has long been used for the
detection of ischemia and even viability. Resting and stress
myocardial perfusion imaging in patients with low-to-
intermediate risk for CAD will identify active inducible
ischemia; however, in patients with recent angina symptoms
SPECT may not be able to identify recent and old infarcts
limiting its speciﬁcity. SPECT is more sensitive than exercise
treadmill testing alone for detecting coronary artery stenosis
of >50% with a sensitivity of 87% and a speciﬁcity of
73%, and with vasodilator stress the sensitivity is 89%
and speciﬁcity is 75% [29] .T h e r ei sm u c hl e s so p e r a t o r
dependency with SPECT imaging, and simultaneous assess-
ment of regional perfusion and function can be obtained. A
study performed in patients with chest pain randomization
to resting SPECT did not alter or aﬀect treatment decisions
in patients with an eventual diagnosis of AMI or UA. SPECT
did reduce the rate of admissions in those without ACS [30].
Limitations with SPECT are that it has imaging protocols
up to 4 hours for stress rest comparison, necessitates radia-
tion exposure, has a lower spatial resolution than echocar-
diography, can underestimate three vessel coronary artery
disease due to balanced ischemia, and can produce many
attenuation artifacts.
7.InvasiveImagingTechniques:IVUS andOCT
Several invasive methods exist to detect and characterize
vulnerable plaque in patients with CHD and IVUS, and
OCT will be discussed further here. Our understanding of
plaque progression and vulnerable plaque characteristics has
been greatly enhanced with IVUS/IVUS virtual histology
(VH) and OCT. In the PROSPECT study, patients presenting
with ACS underwent coronary angiography and IVUS after
PCI. During the 3 year followup, there was a 20% risk of
majoradversecardiovascularevents(MACEs)including13%
in culprit lesions and 12% in nonculprit lesions [31]. The
greatest predictors of this risk were a large plaque burden
of ≥70%, minimal luminal area (MLA) ≤4mm by IVUS
with large necrotic core or TCFA. The highest risk was in
patients with TCFA, increased plaque burden, and decreased
MLA. Patients with long plaques ∼12mm had increased
risk as well. IVUS allows in vivo wall visualization and
the diﬀerentiation of morphological characteristics between
culprit and nonculprit plaques [32]. In a study with serial
IVUS imaging over 12 months ∼75% of TCFA heal during
followup or evolve to less vulnerable plaques. TCFA may
develop from pathological intimal thickening and thick cap
ﬁbroatheromas (ThCFA), and disease progression is more
likely with increased plaque volume [33]. Limits in IVUS
utilization are that it is invasive and thus not ideal for
those not undergoing angiography. IVUS has the inability to
detect TCFA (<65µm) due to its limited spatial resolution
of >100µm, and an inability to accurately distinguish
plaque components [34]. OCT, on the other hand, has high
resolution of 10 to 20µm, ∼10 times that of IVUS [35]. In
ACS, OCT has identiﬁed culprit lesions in STEMI patients
when compared to NSTEMI patients who have more plaque
rupture, TCFA, and red thrombus. Unstable plaques are
deﬁned by TCFA. A cap of <65µm has been observed in 95%
of ruptured plaques [36]. OCT is able to identify rupture-
prone plaques by clearly visualizing large lipid cores, TCFA,
andassessinﬂammation[37].OCTislimited asitisinvasive,
has limited depth penetration making it poor at delineating
lipid content, and is time consuming in that each coronary
artery must be imaged separately. Although IVUS and OCT
require an invasive approach to detect high-risk plaque
characteristics they have been vital in our understanding
of these high-risk indicators and have enabled further
characteristics to be deﬁned by noninvasive measures.
8. Summary
The accurate evaluation, diagnosis, and risk stratiﬁcation of
patients presenting to the clinical setting with chest pain
remains one of the most important clinical processes. ACS
aﬀects millions of people worldwide with costs of evaluating
these patients in the billions. Research and clinical studies
continue to seek for methods that are cost eﬀective, portable,
andhighlyreliableatestablishingadiagnosismoreeﬃciently
so that patients can receive the fastest available treatment
(see Table 1). Several noninvasive measures are available to
the clinician with strengths and weaknesses for each. As
processes in the ED and other clinical settings become more
streamlined, a team-dedicated approach aimed at providing
bestavailablecareisthemostimportant. Protocolsregarding
ACS medications, timeliness of EKG’s, and stratiﬁcation
schemes regarding patients risk proﬁle are the most impor-
tant tools at hand to provide this care. In the subgroup of
patients that are then determined to be low-to-intermediate
risk noninvasive methods should be utilized in the timeliest
manner to further stratify these patients to an early invasive
or more conservative strategy. Clinicians should seek to use
the methods at their facility that are the most accurate, cost
eﬀective, and provide the greatest diagnostic information to
provide their patients with the best available care.
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